{
    "nct_id": "NCT01768195",
    "official_title": "Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* treatment-naive patients with B-cell lymphoma\n* HBsAg positive at baseline\n* treated with rituximab-based immunochemotherapy\n* life expectancy of more than 3 months\n\nExclusion Criteria:\n\n* younger than 18 years old\n* HBsAg negative at baseline\n* pregnant or lactating women\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* treatment-naive patients with B-cell lymphoma\n* HBsAg positive at baseline\n* treated with rituximab-based immunochemotherapy\n* life expectancy of more than 3 months",
        "exclusion": "* younger than 18 years old\n* HBsAg negative at baseline\n* pregnant or lactating women"
    }
}